Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

The Inflation Reduction Act (IRA) has reshaped how Medicare covers and reimburses prescription drugs. For the first time, the federal ...

Fresenius Kabi, an operating company of Fresenius, announced that the Centers for Medicare and Medicaid Services issued a permanent, product-specific billing code for Otulfi (ustekinumab-aauz). Under ...

This stock is one to own during any market environment.